11:09 , Apr 16, 2019 |  BioCentury  |  Emerging Company Profile

Kintai’s host-targeting niche in Flagship microbiome ecosystem

Kintai, Flagship’s latest foray into microbiome-based medicines, is taking bugs out of the equation by developing oral small molecules that mimic microbes’ therapeutic effects. Emerging from stealth mode Tuesday and led by Paul-Peter Tak as...
07:00 , Aug 15, 2016 |  BC Week In Review  |  Company News

Polyphor, Gilead deal

Gilead and Polyphor partnered to discover and develop macrocycle molecules for targets selected by Gilead. Polyphor will receive an undisclosed upfront payment and research funding and is eligible for milestones. Polyphor will use its MacroFinder...
07:00 , Sep 1, 2014 |  BC Week In Review  |  Company News

BTG sales and marketing update

BTG launched Varithena in the U.S. to treat varicose veins. The wholesale acquisition cost (WAC) for a 45 mL tube of 10 mg/mL Varithena is $3,195. The polidocanol endovenous microfoam ( PEM ) is administered...
08:00 , Dec 9, 2013 |  BC Week In Review  |  Clinical News

Varithena regulatory update

FDA approved an NDA from BTG for Varithena to treat varicose veins. BTG plans to launch the polidocanol endovenous microfoam ( PEM ) in the U.S. in 2Q14 BTG plc (LSE:BTG), London, U.K.   Product:...
01:10 , Nov 27, 2013 |  BC Extra  |  Company News

FDA approves BTG's varicose vein product

BTG plc (LSE:BTG) jumped 63.10p (14%) to 522p on Tuesday after FDA approved an NDA from the company for Varithena (formerly known as Varisolve ) to treat varicose veins. BTG plans to launch the polidocanol...
07:00 , Apr 15, 2013 |  BC Week In Review  |  Clinical News

Varisolve regulatory update

BTG said FDA accepted for review an NDA for Varisolve to treat varicose veins. The company submitted the application in early February. The exact PDUFA date is not disclosed, but BTG said the polidocanol endovenous...
23:54 , Apr 12, 2013 |  BC Extra  |  Company News

FDA to review BTG's Varisolve

BTG plc (LSE:BTG) said FDA accepted for review an NDA for Varisolve to treat varicose veins. The company submitted the application in early February. The exact PDUFA date is not disclosed, but BTG said the...
07:00 , Mar 11, 2013 |  BC Week In Review  |  Clinical News

Cu-64-TP3805 diagnostic data

Researchers at Thomas Jefferson University reported data from 13 breast cancer patients showing that Positron Emission Mammography (PEM) imaging using Cu-64-TP3805 had 100% sensitivity and 100% specificity for distinguishing malignant from benign breast cancer lesions....
08:00 , Feb 11, 2013 |  BC Week In Review  |  Clinical News

Varisolve regulatory update

BTG said it submitted an NDA to FDA for Varisolve to treat varicose veins. Last year, BTG said the polidocanol endovenous microfoam ( PEM ) met the primary endpoint of improving patient-reported varicose vein symptoms...
01:58 , Feb 5, 2013 |  BC Extra  |  Company News

BTG submits Varisolve NDA

BTG plc (LSE:BTG) said it submitted an NDA to FDA for Varisolve to treat varicose veins. Last year, BTG said the polidocanol endovenous microfoam ( PEM ) met the primary endpoint of improving patient-reported varicose...